Indication
Common variable agammaglobulinemia
Common variable agammaglobulinemia, widely referred to in modern clinical practice as common variable immunodeficiency (CVID), is a heterogeneous primary antibody deficiency syndrome. Read more about Common variable agammaglobulinemia
45 drugs 17 manufacturers
Drugs that treat it
Common Common variable agammaglobulinemia therapies.
GAMMAPLEX (immune globulin,gamma(IgG))
HIZENTRA (immune globulin,gamma (IgG)/proline/IgA 0 to 50 mcg/mL)
BIVIGAM (immune globulin,gamma(IgG))
PRIVIGEN (immune globulin,gamma(IgG))
CARIMUNE NF NANOFILTERED (immune globulin,gamma(IgG))
HYQVIA (immune globulin,gamma(IgG) human/hyaluronidase, human recomb)
GAMMAGARD LIQUID (immune globulin,gamm(IgG)/glycine/IgA greater than 50 mcg/mL)
FLEBOGAMMA DIF (immune globulin,gamma (IgG)/sorbitol/IgA 0 to 50 mcg/mL)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCommon variable agammaglobulinemia, widely referred to in modern clinical practice as common variable immunodeficiency (CVID), is a heterogeneous primary antibody deficiency syndrome.
It primarily compromises the humoral immune system, affecting both children and adults, with clinical onset most frequently identified in the second through fourth decades of life.
The condition is pathologically defined by defective B-cell differentiation resulting in markedly reduced serum IgG concentrations along with low IgA and/or IgM, accompanied by impaired or absent specific antibody responses to protein and polysaccharide antigens despite normal or near-normal circulating B-cell numbers.
Clinically, affected individuals suffer from recurrent sinopulmonary bacterial infections, bronchiectasis, gastrointestinal disease, and a heightened vulnerability to autoimmune disorders, granulomatous inflammation, and lymphoid malignancies.
- nih.gov
Common variable agammaglobulinemia, widely referred to in modern clinical practice as common variable immunodeficiency (CVID), is a heterogeneous primary antibody deficiency syndrome
- nih.gov
Common variable agammaglobulinemia, widely referred to in modern clinical practice as common variable immunodeficiency (CVID), is a heterogeneous primary antibody deficiency syndrome
- medlineplus.gov
It primarily compromises the humoral immune system, affecting both children and adults, with clinical onset most frequently identified in the second through fourth decades of life Clinically, affected individuals suffer from recurrent sinopulmonary bacterial infections, bronchiectasis, gastrointestinal disease, and a heightened vulnerability to autoimmune disorders, granulomatous inflammation, and lymphoid malignancies
- nih.gov
The condition is pathologically defined by defective B-cell differentiation resulting in markedly reduced serum IgG concentrations along with low IgA and/or IgM, accompanied by impaired or absent specific antibody responses to protein and polysaccharide antigens despite normal or near-normal circulating B-cell numbers
- alliancegenome.org
The condition is pathologically defined by defective B-cell differentiation resulting in markedly reduced serum IgG concentrations along with low IgA and/or IgM, accompanied by impaired or absent specific antibody responses to protein and polysaccharide antigens despite normal or near-normal circulating B-cell numbers
- nih.gov
Clinically, affected individuals suffer from recurrent sinopulmonary bacterial infections, bronchiectasis, gastrointestinal disease, and a heightened vulnerability to autoimmune disorders, granulomatous inflammation, and lymphoid malignancies
- youtube.com
Clinically, affected individuals suffer from recurrent sinopulmonary bacterial infections, bronchiectasis, gastrointestinal disease, and a heightened vulnerability to autoimmune disorders, granulomatous inflammation, and lymphoid malignancies
Personalize your experience
Follow Common variable agammaglobulinemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.